SELLAS Life Sciences Expands Scientific Advisory Board By Adding Two World-Renowned Experts In Hematology and Oncology

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company developing innovative cancer therapies, has announced the addition of two experienced oncology experts, Dr. Philip C. Amrein and Dr. Alex Kentsis, to its Scientific Advisory Board (SAB). Both new members bring extensive backgrounds in cancer research, clinical practice, and translational medicine. Their involvement is expected to provide valuable scientific and clinical insights as SELLAS continues to advance its pipeline of novel oncology therapies targeting a wide range of cancer types. 

Dr. Amrein and Dr. Kentsis join the SAB at a time when SELLAS is focused on strengthening its strategic approach to late-stage development and clinical advancement of its investigational therapies. Their combined experience will support the company in shaping its research priorities, optimizing trial designs, and guiding future development efforts in oncology.

Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, stated, “We are honored to welcome Drs. Amrein and Kentsis to our Scientific Advisory Board. Their extensive experience in clinical development and hematology-oncology research will be pivotal as we reach significant milestones with both of our assets, full topline Phase 2 data of SLS009 in acute myeloid leukemia (AML), and the final analysis of our Phase 3 pivotal REGAL trial of GPS in AML.”

He continued, “With those inflection points expected this year, their guidance will help ensure we continue to advance our lead assets towards potential regulatory filings and commercialization, while also supporting our efforts in translational and precision medicine to maximize clinical impact. We are thrilled to collaborate with them, leveraging their exceptional expertise to drive groundbreaking success.”